Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Nivolumab + Chemo for Salivary Gland Carcinoma
NCT05727410Phase 2Recruiting
- Start
- Nov 2022
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in salivary gland carcinoma (SGC). Started Nov 2022; status: recruiting.
02
Drugs
03
Conditions
salivary gland carcinoma (SGC)
Beyond the preview
Go deeper on NCT05727410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05727410.